CatalYm GmbH: CatalYm Commences Phase 2 Development of GDF-1

CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of

Related Keywords

Spain , Germany , Switzerland , Kostenloser Wertpapierhandel , Catalym Gmb , Phil Lhuillier , Ignacio Melero Center , World Health Organization , International Nonproprietary Name , Trophic Communications , Differentiation Factor , Ted Human Effector , Ignacio Melero , Advanced Medical Research , Principal Investigator , Eugen Leo , Chief Medical Officer , Phill Huillier , Growth Differentiation , Laura Mittmann , Stephanie May , Catalym , Mbh , Ommences , Hase , Development , Targeting , Ntibody , Following , Uccessful , Completion ,